LipoCoat Holdings (“LipoCoat”), a portfolio company from 819 Capital Partners, strategically acquired Sono-Coat. The deal is backed by a growth investment directly into Sono-Coat BV (“Sono-Coat”) led by 819 Capital Partners (“819”) from their 819 Evergreen Fund.
Sono-Coat has developed patented echogenic coating solutions that offer unsurpassed ultrasound visibility for medical devices, enabling novel ultrasound guided therapies.
Strategic acquisition with strong synergy potential
The strategic acquisition of the Sono-Coat technology marks a significant extension of LipoCoat’s mission to improve the comfort, safety, and performance of medical devices through innovative coating solutions, to address the evolving needs of researchers, clinicians, and patients worldwide.
“We are thrilled to welcome Sono-Coat to the LipoCoat family” said Jasper van Weerd, CEO LipoCoat Holdings. “Their innovative echogenic coating technology complements our existing technologies and aligns perfectly with our commitment to delivering superior solutions that improve patient outcomes. Together, we will accelerate the pace of innovation in the biomedical field and create value for our customers and partners.”
For 819, leading the growth investment makes sense, as Sono-Coat offers an attractive value proposition with potential synergy with portfolio company LipoCoat. Wim Smit, managing partner at 819: “Sono-Coat has developed a strong solution to enhance visibility of needles and catheters, thereby making work of doctors easier. We see, besides a stand-alone success, several benefits in the combination with LipoCoat: both cross-selling opportunities and the development of a combined product.”
Beneficial collaboration for all parties involved
Lee Ayres, CTO and inventor of Sono-Coat is excited to join the LipoCoat Group. “Together with LipoCoat, we can leverage our collective expertise to drive innovation and bring transformative solutions to market faster. This union represents a win-win for our customers, who will benefit from a broader range of high-quality products and services. The Sono-Coat technology can be applied to a wide range of devices, in diverse fields such as interventional radiology, ablation, regional anesthesia, central lines and structural heart.”
With the acquisition of Sono-Coat, LipoCoat extends the commitment to advancing healthcare through innovation. By harnessing the synergies between LipoCoat and Sono-Coat, the group further strengthens its position as a preferred partner for researchers and industry stakeholders seeking cutting-edge solutions to address complex biomedical challenges.
